Hims & Hers Health Management
Management Kriterienprüfungen 2/4
Hims & Hers Health CEO ist Andrew Dudum , ernannt in Jan 2017, hat eine Amtszeit von 7.83 Jahren. Die jährliche Gesamtvergütung beträgt $14.40M , bestehend aus 4.2% Gehalt und 95.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 8.61% der Aktien des Unternehmens, im Wert von $410.08M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.7 Jahre bzw. 2.9 Jahre.
Wichtige Informationen
Andrew Dudum
Geschäftsführender
US$14.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 4.2% |
| Amtszeit als Geschäftsführer | 7.8yrs |
| Eigentum des Geschäftsführers | 8.6% |
| Durchschnittliche Amtszeit des Managements | 2.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.9yrs |
Jüngste Management Updates
Recent updates
Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01
Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Vergütung im Vergleich zum Markt: AndrewDie Gesamtvergütung ($USD14.40M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.60M).
Entschädigung vs. Einkommen: AndrewDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Andrew Dudum (35 yo)
7.8yrs
Amtszeit
US$14,401,411
Vergütung
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Financial Officer | 2.8yrs | US$7.43m | 0.051% $ 2.4m | |
| Chief Operating Officer | 3.8yrs | US$6.77m | 0.29% $ 13.7m | |
| Chief Legal Officer & Corporate Secretary | 3.8yrs | US$5.21m | 0.077% $ 3.7m | |
| Chief Medical Officer | 1.9yrs | US$198.26k | 0.088% $ 4.2m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.084% $ 4.0m | |
| Senior VP | 5.4yrs | US$961.12k | 0.0023% $ 111.4k | |
| Chief Communications Officer | 1.1yrs | keine Daten | keine Daten | |
| Senior Vice President of Human Resources | 2.7yrs | keine Daten | keine Daten | |
| Senior VP & Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Chief Pharmacy & Innovation Officer | 1.9yrs | keine Daten | keine Daten | |
| Senior Vice President of Mental Health | 1.7yrs | keine Daten | keine Daten |
2.7yrs
Durchschnittliche Betriebszugehörigkeit
44yo
Durchschnittliches Alter
Erfahrenes Management: HIMSDas Führungsteam des Unternehmens gilt als erfahren (2.7 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder | 3.8yrs | US$14.40m | 8.61% $ 410.1m | |
| Chief Medical Officer | 2.8yrs | US$198.26k | 0.088% $ 4.2m | |
| Senior VP & Member of Medical Advisory Board | 2.8yrs | keine Daten | keine Daten | |
| Independent Director | 4.2yrs | US$194.26k | 0.025% $ 1.2m | |
| Lead Independent Director | 4.2yrs | US$227.41k | 0.071% $ 3.4m | |
| Independent Director | 3.7yrs | US$205.51k | 0.033% $ 1.6m | |
| Member of Medical Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | no data | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 2.9yrs | keine Daten | keine Daten | |
| Member of Medical Advisory Board | 2.9yrs | keine Daten | keine Daten |
2.9yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter
Erfahrener Vorstand: HIMSDie Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.